Many patients do not reach target cholesterol levels because of the underdosed statin treatment. The IMPROVE-IT study shows that a further lowering of the LDL cholesterol in patients on statins after an acute coronary syndrome by ezetimibe leads to a further cardiovascular risk reduction.